IBD patients with prior or coexisting cancer receive distinct medical therapies and face increased surgery risk.
Background
The increasing overlap between inflammatory bowel diseases (IBD) and cancer due to an aging population and rising IBD incidence presents a significant clinical challenge. Managing IBD in patients with a cancer history or concurrent malignancy creates a dilemma. Current IBD treatment strategies often involve immunosuppressants, raising concerns about cancer recurrence or progression. This necessitates a careful balance between controlling IBD activity and minimizing oncological risks, a critical gap this study aims to explore.
Study Design
Researchers conducted a Danish nationwide cohort study from 1996 to 2022, utilizing national registers to identify 59,494 incident and prevalent patients with inflammatory bowel disease (IBD). The cohort included 20,551 patients with Crohn's disease (CD) and 38,943 with ulcerative colitis (UC). Data on drug exposure (e.g., immunomodulators, anti-tumor necrosis factor [anti-TNF] agents) and cancer status were extracted. Cox regression models compared medication use and the risk of IBD-related surgery between patients with and without a cancer history.
Results
The study identified 2675 (4.5%) IBD patients diagnosed with cancer prior to their IBD diagnosis. Among the remaining 56,819 IBD patients, 6636 (11.7%) developed their first cancer after their IBD diagnosis. Patients with prior cancer showed reduced immunomodulator use for both CD and UC. Conversely, UC patients with a prior cancer history exhibited increased use of anti-TNF therapies. Notably, patients who developed cancer during their IBD course largely had their anti-TNF and immunomodulator therapies discontinued following the cancer diagnosis. This indicates a significant shift in treatment approach based on cancer status.
Patients with CD and UC and a history of cancer had an increased risk of undergoing IBD-related surgery during follow-up.
Key Findings
- 4.5% of IBD patients had a prior cancer diagnosis, and 11.7% developed cancer after IBD diagnosis.
- Prior cancer was associated with reduced immunomodulator use for both Crohn's disease and ulcerative colitis.
- Ulcerative colitis patients with prior cancer showed increased anti-TNF therapy use.
- IBD patients with a cancer history faced an increased risk of IBD-related surgery.
- Anti-TNF and immunomodulator therapies were largely discontinued after a new cancer diagnosis in IBD patients.
Why It Matters
This study provides crucial real-world evidence for clinicians managing IBD in patients with a history of or coexisting cancer. The observed differences in treatment patterns and increased surgical risk highlight the need for tailored, evidence-based guidelines. Clinicians should exercise greater caution when initiating or reinitiating immunosuppressants in IBD patients with cancer, potentially favoring therapies with lower perceived oncogenic risk or more localized action. The higher surgical rates suggest that current cautious approaches to medical therapy may lead to inadequate disease control, underscoring the need for novel, safer therapeutic options that can effectively manage IBD without exacerbating cancer risk. This also implies a potential gap in current protocols for balancing IBD control and cancer surveillance.
ibd
cancer
treatment
cohort-study
immunosuppression
anti-tnf